文献速递头颈部肿瘤放疗放疗物理与技术

利用PSMA PET对唾液腺分泌细胞丢失进行剂量效应建模

Dose response modelling of secretory cell loss in salivary glands using PSMA PET.
PubMed 文献 · Radiother Oncol · 2022-11-08

研究纳入28例接受70 Gy/35次/7周放疗的头颈癌患者,在基线、治疗中及治疗后1和6个月行PSMA PET/CT,体素水平分析腮腺与颌下腺SUV的剂量效应。剂量每增加1 Gy,腮腺治疗后1和6个月SUV分别下降1.6%和1.6%,颌下腺分别下降0.9%和1.8%;腮腺TD50分别为26.5和31.3 Gy,颌下腺分别为22.9和27.8 Gy。PSMA丢失与患者报告的口干在治疗中及治疗后1个月相关(Spearman ρ=-0.64和-0.50)。

要点

  • 剂量每增1 Gy,腮腺治疗后1和6个月SUV各降1.6%,颌下腺降0.9%和1.8%。
  • 腮腺TD50为26.5和31.3 Gy,颌下腺为22.9和27.8 Gy(治疗后1和6个月)。
  • PSMA丢失与患者报告口干在治疗中及治疗后1个月相关(ρ=-0.64和-0.50)。

核心结论

  • PSMA PET/CT显示唾液腺分泌细胞丢失与放疗剂量呈强相关,人群曲线或可作为剂量规划目标,基线扫描或可进一步个体化调整。

研究设计与样本

  • 28例头颈癌患者接受70 Gy/35次/7周放疗,于基线、治疗中及治疗后1和6个月行PSMA PET/CT,对腮腺和颌下腺每个体素提取剂量与SUV,治疗后数据用广义线性混合效应模型分析。

主要发现

  • 对基线SUV为10的人群平均腺体,剂量每增加1 Gy,腮腺治疗后1和6个月SUV分别下降1.6%和1.6%,颌下腺分别下降0.9%和1.8%。
  • 腮腺人群曲线TD50在治疗后1和6个月分别为26.5 Gy和31.3 Gy,颌下腺分别为22.9 Gy和27.8 Gy。
  • PSMA丢失与患者报告口干在治疗中和治疗后1个月相关(Spearman ρ=-0.64和-0.50)。

临床怎么用

  • 作者认为人群曲线或可作为剂量规划目标,通过最大化预测的治疗后SUV来减少分泌细胞丢失。
  • 作者认为基线扫描或可进一步用于个体化调整该剂量规划目标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Xerostomia remains a common side effect of radiotherapy (RT) for patients with head and neck (H&N) cancer despite advancements in treatment planning and delivery. Secretory salivary gland cells express the prostate-specific membrane antigen (PSMA), and show significant uptake on PET scans using 68Ga/18F-PSMA-ligands. We aimed to objectively quantify the dose-response of salivary glands to RT using PSMA PET. METHODS AND MATERIALS: 28H&N cancer patients received RT with 70 Gy in 35 fractions over 7 weeks. PSMA PET/CT was acquired at baseline (BL), during treatment (DT) and at 1-&6-months post-treatment (PT1M/PT6M). Dose, BL- PT1M- and PT6M-SUV were extracted for every voxel inside each parotid (PG) and submandibular (SMG) gland. The PT1M/6M data was analysed using a generalised linear mixed effects model.Patient-reported xerostomia and DT-PSMA loss was also analysed. RESULTS: Dose had a relative effect on BL SUV. For a population average gland (BL-SUV of 10), every 1 Gy increment, decreased the PT1M/PT6M-SUV by 1.6 %/1.6 % for PGs and by 0.9 %/1.8 % for SMGs. TD50 of the population curves was 26.5/31.3 Gy for PGs, and 22.9/27.8 Gy for SMGs at PT1M /PT6M. PSMA loss correlated well with patient-reported xerostomia at DT/PT1M (Spearman's ρ = -0.64, -0.50). CONCLUSION: A strong relationship was demonstrated between radiation dose and loss of secretory cells in salivary glands derived using PSMA PET/CT. The population curve could potentially be used as a dose planning objective, by maximising the predicted post-treatment SUV. BL scans could be used to further tailor this to individual patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mohan V, Bruin NM, Steenbakkers RJHM, et al. Dose response modelling of secretory cell loss in salivary glands using PSMA PET. Radiother Oncol. 2022. PMID: 36368471. doi:10.1016/j.radonc.2022.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。